Engineers Gate Manager LP Reduces Holdings in Dianthus Therapeutics, Inc. $DNTH

Key Points

• Engineers Gate Manager LP cut its Dianthus Therapeutics stake by 47.1% in the second quarter, selling 10,330 shares and retaining 11,580 shares valued at approximately $1.13 million. Institutional investors collectively own 47.53% of DNTH.
• Dianthus shares opened at $96.81, down 4.3%, while the company reported a quarterly loss of $0.90 per share—below the $0.85 consensus estimate—despite revenue of $760,000 exceeding expectations.
• Wall Street remains broadly bullish: analysts’ average rating is “Moderate Buy,” with an average price target of $129.83. However, insiders sold $29.3 million worth of shares over the past three months.

Engineers Gate Manager LP decreased its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 47.1% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,580 shares of the company's stock after selling 10,330 shares during the period. Engineers Gate Manager LP's holdings in Dianthus Therapeutics were worth $1,129,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Arizona State Retirement System grew its holdings in Dianthus Therapeutics by 5.7% during the 2nd quarter. Arizona State Retirement System now owns 10,141 shares of the company's stock valued at $989,000 after purchasing an additional 546 shares during the last quarter. Nykredit A S purchased a new position in shares of Dianthus Therapeutics during the second quarter valued at approximately $147,000. Amundi bought a new position in shares of Dianthus Therapeutics during the second quarter valued at approximately $287,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Dianthus Therapeutics during the second quarter valued at approximately $1,033,000. Finally, Alyeska Investment Group L.P. raised its holdings in shares of Dianthus Therapeutics by 188.2% in the second quarter. Alyeska Investment Group L.P. now owns 150,592 shares of the company's stock worth $14,680,000 after buying an additional 98,345 shares during the period. Hedge funds and other institutional investors own 47.53% of the company's stock.

Insiders Place Their Bets

In other news, CAO Edward Carr sold 20,000 shares of the firm's stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $101.38, for a total value of $2,027,600.00. Following the sale, the chief accounting officer directly owned 20,000 shares in the company, valued at approximately $2,027,600. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Ryan Savitz sold 31,249 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the completion of the transaction, the executive vice president directly owned 31,249 shares in the company, valued at approximately $3,157,086.47. The trade was a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 273,678 shares of company stock valued at $29,276,000 in the last three months. 3.02% of the stock is currently owned by insiders.

Dianthus Therapeutics Stock Down 4.3%

Shares of DNTH stock opened at $96.81 on Friday. The firm has a market cap of $5.29 billion, a price-to-earnings ratio of -23.33 and a beta of 1.24. Dianthus Therapeutics, Inc. has a 52-week low of $32.22 and a 52-week high of $117.88. The company's 50 day moving average is $107.03 and its 200 day moving average is $92.84.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The company had revenue of $0.76 million for the quarter, compared to analysts' expectations of $0.30 million. Analysts anticipate that Dianthus Therapeutics, Inc. will post -3.81 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on DNTH. Guggenheim reissued a "buy" rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Truist Financial raised their price target on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Wolfe Research reiterated an "outperform" rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Citigroup began coverage on shares of Dianthus Therapeutics in a research report on Friday, September 4th. They issued a "buy" rating and a $156.00 price objective for the company. Finally, HC Wainwright upped their target price on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $129.83.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for complement-mediated diseases. The complement system is part of the immune system, and abnormal activation can contribute to autoimmune and inflammatory disorders. Dianthus is developing therapies designed to selectively inhibit complement activity while offering potentially durable treatment effects.

The company's lead product candidate, DNTH103, is an investigational monoclonal antibody designed to inhibit C1s, a protein involved in the classical complement pathway.

Want to see what other hedge funds are holding DNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.